Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$6.05 - $8.65 $135,671 - $193,976
-22,425 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$7.35 - $12.0 $18,742 - $30,600
-2,550 Reduced 10.21%
22,425 $189,000
Q3 2021

Nov 12, 2021

SELL
$8.65 - $11.64 $353,335 - $475,470
-40,848 Reduced 62.06%
24,975 $283,000
Q2 2021

Aug 13, 2021

BUY
$9.1 - $14.71 $391,145 - $632,279
42,983 Added 188.19%
65,823 $649,000
Q1 2021

May 13, 2021

SELL
$8.98 - $12.86 $509,929 - $730,255
-56,785 Reduced 71.32%
22,840 $283,000
Q4 2020

Feb 10, 2021

BUY
$5.61 - $13.47 $11,781 - $28,287
2,100 Added 2.71%
79,625 $688,000
Q3 2020

Nov 13, 2020

BUY
$3.33 - $8.26 $38,158 - $94,651
11,459 Added 17.34%
77,525 $523,000
Q2 2020

Aug 13, 2020

BUY
$2.56 - $3.6 $81,512 - $114,627
31,841 Added 93.03%
66,066 $224,000
Q1 2020

May 14, 2020

SELL
$2.72 - $4.64 $4,436 - $7,567
-1,631 Reduced 4.55%
34,225 $99,000
Q4 2019

Feb 13, 2020

BUY
$2.84 - $7.4 $4,348 - $11,329
1,531 Added 4.46%
35,856 $156,000
Q4 2018

Feb 13, 2019

BUY
$2.2 - $3.18 $75,515 - $109,153
34,325 New
34,325 $83,000

Others Institutions Holding KZIA

About KAZIA THERAPEUTICS LTD


  • Ticker KZIA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,111,300
  • Market Cap $47M
  • Description
  • Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...
More about KZIA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.